Horizon Space Acquisition II Corp. SEC filings document its status as a Cayman Islands blank-check issuer and the securities used in its SPAC structure. The record includes Form 8-K material-event reports covering material definitive agreements, direct financial obligations, charter amendment and deadline-extension matters, shareholder votes, governance topics, and capital-structure disclosures for ordinary shares, units, and rights listed under HSPT, HSPTU, and HSPTR. Filings also include annual-report timing notices and disclosure categories such as operating results, financial condition, risk factors, and emerging growth company status.
Horizon Space Acquisition II Corp. filed a Form 8-K related to its proposed business combination with SL BIO Ltd., updating details in its definitive proxy statement for the February 3, 2026 extraordinary general meeting. The filing corrects references to the trust account trustee, confirming Wilmington Trust, National Association, and clarifies contact details for the proxy solicitor Advantage Proxy, Inc. and transfer agent VStock Transfer, LLC.
The update restates shareholders’ redemption rights, including that public shareholders may redeem their shares for cash based on funds in the trust account, with a redemption deadline of 5:00 pm Eastern Time on January 30, 2026. It explains how unit holders must separate units, the DWAC and physical certificate processes, and notes that significant redemptions could reduce liquidity and potentially affect Nasdaq listing standards for the post-merger PubCo, though Nasdaq listing approval remains a condition to closing the business combination.
Horizon Space Acquisition II Corp. filed a Form 8-K to update its definitive proxy materials for the proposed business combination with SL BIO Ltd. The filing corrects references to key service providers, confirming Wilmington Trust, National Association as trustee of the SPAC’s trust account and VStock Transfer, LLC as the transfer agent handling share deliveries and redemptions.
The updated language explains how public shareholders can redeem their shares for cash from the trust account in connection with the February 3, 2026 extraordinary general meeting, including the requirement to submit a written request and deliver shares to VStock two business days before the vote, by 5:00 pm Eastern Time on January 30, 2026. It also notes that rights have no redemption feature and warns that significant redemptions could reduce liquidity and may affect the combined company’s ability to meet Nasdaq listing standards, even if the business combination is approved.
Horizon Space Acquisition II Corp. updated details for its planned business combination with SL BIO Ltd. and the related shareholder vote. The company corrected references in its definitive proxy materials to show Wilmington Trust, National Association as trustee of the SPAC trust account, Advantage Proxy, Inc. as proxy solicitor, and VStock Transfer, LLC as transfer agent and redemption contact.
The extraordinary general meeting to vote on the business combination remains set for February 3, 2026, with a redemption election deadline of 5:00 p.m. Eastern Time on January 30, 2026. Public shareholders may redeem shares for cash from the trust account regardless of how they vote, but significant redemptions could reduce liquidity in the post‑merger company’s shares and may affect the ability to meet Nasdaq listing standards.
Horizon Space Acquisition II Corp. describes updates to its proxy materials for the proposed business combination with SL BIO Ltd. The company clarifies that the SPAC trust account is maintained by Wilmington Trust, National Association as trustee and provides corrected contact information for its proxy solicitor, Advantage Proxy, Inc., and transfer agent, VStock Transfer, LLC.
The 8-K restates how public shareholders can redeem their shares in connection with the business combination, including that each public share may be redeemed for cash equal to the funds in the trust account divided by the public shares outstanding. The Redemption Deadline is 5:00 pm Eastern Time on January 30, 2026, two business days before the Extraordinary Meeting scheduled for February 3, 2026
Horizon Space Acquisition II Corp. is soliciting shareholder approval for a business combination with SL Bio, tied to a prospectus for up to 567,018,150 PubCo ordinary shares. The deal will be executed through two mergers that make both HSPT and SL Bio wholly owned subsidiaries of SL Science Holding Limited (PubCo), whose ordinary shares are expected to list on Nasdaq under “SLBT.” SL Bio is valued at $5.568 billion, with SL Bio shareholders and HSPT investors receiving PubCo stock based on agreed exchange mechanics and any redemptions.
HSPT public shareholders may redeem their shares for cash from the trust account (about $10.53 per share as of December 29, 2025), subject to a 15% cap for any one holder or group. The sponsor will convert founder and private securities into PubCo shares and is expected to hold less than 1% of PubCo voting power, while SL Bio’s CEO William Wang is expected to control about 59%, making PubCo a “controlled company” and a foreign private issuer with more flexible U.S. governance and reporting requirements.
SL Science Holding Limited is registering up to 567,018,150 PubCo Ordinary Shares in connection with its proposed business combination with Horizon Space Acquisition II Corp. (HSPT) and SL BIO Ltd. The deal uses a two-step merger where HSPT and SL Bio each become wholly owned subsidiaries of a Cayman holding company, PubCo, with all HSPT and SL Bio equity holders receiving PubCo Ordinary Shares.
The SL Bio equity is valued at $5.568 billion, based on $10.00 per share. PubCo expects to list its shares on Nasdaq under the symbol “SLBT.” HSPT public shareholders can redeem their shares for cash at a pro rata trust value, which was approximately $10.53 per share as of December 29, 2025, versus a market price of $10.55.
The parties will use reasonable best efforts to secure at least $5,000,000 in equity Transaction Financing, although no commitments have been received. Sponsor economics include founder and private shares and potential units from up to $2,500,000 of working capital loans, but the sponsor is expected to hold under 1% of PubCo voting power. After closing, CEO William Wang is expected to control about 59% of voting power, making PubCo a “controlled company” and a foreign private issuer with more flexible governance and reporting requirements than a typical U.S. domestic issuer.
SL Science Holding Limited has filed a Form F-4 to register ordinary shares to be issued in a two-step business combination among itself, Horizon Space Acquisition II Corp. (HSPT) and SL BIO Ltd. After closing, HSPT and SL Bio will become subsidiaries of SL Science Holding, whose ordinary shares are expected to trade on the Nasdaq Global Market under the symbol “SLBT.”
The exchange ratio for SL Bio shareholders is based on a valuation reference of $5.568 billion at $10.00 per PubCo share, while each HSPT ordinary share will convert into one PubCo ordinary share after unit separation and right conversion. The deal targets at least $5,000,000 of third‑party equity “Transaction Financing,” and HSPT public shareholders may redeem their shares for cash from the trust account subject to a 15% cap for any group. Post‑merger, CEO William Wang is expected to hold about 58% of PubCo’s voting power, making it a “controlled company” and a Cayman‑incorporated foreign private issuer with lighter U.S. governance and reporting requirements; the board obtained a fairness opinion from King Kee Appraisal and Advisory Limited in supporting the transaction.
Horizon Space Acquisition II Corp. entered into a new unsecured promissory note for $690,000 with a sponsor designee to fund an extension of its SPAC deadline. On or about November 17, 2025, the same amount was deposited into the trust account, allowing the company to extend the time to complete its initial business combination by three months, from November 18, 2025 to February 18, 2026. The note bears no interest and is repayable at the earlier of a business combination or the company’s expiry, and the lender may instead convert the balance into private units at $10.00 per unit, each unit consisting of one ordinary share and a right to receive one-tenth of an ordinary share upon a business combination.
Horizon Space Acquisition II Corp. (HSPT) filed its quarterly report for the period ended September 30, 2025. The SPAC remains pre‑revenue, with activity centered on its IPO proceeds and proposed merger plans. Net income was $615,026 for the quarter, driven by $739,550 of interest and dividend income from the Trust Account, offset by $124,524 of formation and operating costs. For the nine months, net income totaled $1,308,900.
The Trust Account balance was $71,540,599, while cash outside the trust was $66,627. Ordinary shares subject to possible redemption were 6,900,000 at redemption value; non‑redeemable ordinary shares outstanding were 2,180,000. The company reported a working capital deficit of $436,294 and recorded accretion to redemption value of $739,550 in the quarter.
Management disclosed substantial doubt about the company’s ability to continue as a going concern. The combination deadline is November 18, 2025 (extendable to May 18, 2026 with sponsor deposits of $690,000 per three‑month extension, up to $1,380,000). On May 9, 2025, HSPT entered a business combination agreement with SL Science Holding Limited and SL Bio Ltd. The sponsor provided a $300,000 non‑interest bearing working capital note on July 5, 2025.
Horizon Space Acquisition II Corp. is a Cayman Islands blank‑check company formed to complete a business combination. The company completed an IPO and related private placements that produced gross proceeds of $69,000,000 and, as of June 30, 2025, held $70,801,049 in a Trust Account that will fund an initial business combination. Cash outside the Trust was $26,030 and the company reported a working capital deficit of $311,770.
The company reported net income of $221,282 for Q2 2025 and $693,874 for the six months ended June 30, 2025, primarily from interest and dividend income on the Trust Account of $730,448 (Q2) and $1,456,519 (six months). On May 9, 2025, the company entered into a business combination agreement with SL Bio (through PubCo), and on July 5, 2025 the sponsor provided a $300,000 unsecured promissory note for working capital. Management disclosed that conditions raise substantial doubt about the company’s ability to continue as a going concern and plans to address this through working capital loans.